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To the Editor; 
 
It was with interest that I read the recent article by Zhang et al. published in 
Supportive Care in Cancer [1]. This paper highlighted the importance of 
radiodermatitis (RD) being an unresolved and distressing clinical issue in patients 
with cancer undergoing radiation therapy.  However, I am concerned with a number 
of clinical and methodological issues within this paper: (i) the clinical and operational 
definition of prophylaxis and treatment of RD; (ii) the accuracy of the identification 
of trials; and (iii) the appropriateness of the conduct of the meta-analyses.  
 
First of all, it is important to establish the definitions of prophylaxis and treatment of 
RD. It has been repeatedly reported that there have not been any globally accepted 
definitions of prophylaxis and treatment in this area [2]. In some cases, the aim of 
prophylaxis may be to reduce “the time to a certain grade of RD”. For others, it could 
be the prevention of any reaction altogether. Indeed, a small group of patients may 
never develop any reaction from their radical treatment even when they receive a 
considerable dosage of radiation. Given meta-analysis was the primary objective of 
this paper, it was very important that these definitions were made clear as they could 
have tremendous implications on the pooling of data. For these reasons, I suggest that, 
for future studies and reviews, true “prophylaxis” should be reserved for use if the 
intent is to prevent a reaction from occurring (yes or no) [2]. And “treatment” should 
be used to refer to any other management strategies and outcomes after the onset of 
any graded RD [2]. 
 
Secondly, Zhang’s paper was designed to only include randomised controlled trials 
(RCT). However, Masferrer et al (2010) was not a RCT, but a prospective 
observational study [3]. Although Zhang et al’s paper is titled as a “meta-analysis”, 
and not a systematic review, the quality standards for the identification of trials 
should be upheld. Duplicate study identification, where possible, can be performed 
for the conduct of all systematic reviews or meta-analyses. The omission of eligible 
studies or wrong inclusion of studies could have a direct impact on the validity and 
direction of results [4].  
 
Thirdly, I would like to comment on the appropriateness of the conduct of meta-
analyses. One single most common criticism of meta-analyses is that they combine 
“apples” with “oranges” [5]. Such argument should not mean that meta-analyses 
cannot be conducted at all. Rather, it should be conducted with sufficient clinical 
justification and methodological testings (i.e. identifying, measuring and addressing 
heterogeneity). Although sub-group analysis by each individual intervention 
comparison might not be feasible, it does not necessarily mean that the conduct of a 
meta-analysis including a diverse range of topical interventions is justified. These 
topical interventions could range from corticosteroid to antioxidant solution. Last but 
not least, it is very crucial that the results of the meta-analyses are interpreted with 
caution. Zhang et al concluded that topical agents could not prevent or treat RD [1], 
based on two meta-analyses comprising a number of trials [6-10] that compared one 
topical intervention with another topical treatment. The differences of effects in these 
trials should be used to conclude the effects between treatments, rather than the 
effects of “topical treatments”. 
 
A number of reviews have now been conducted in this space [2]. There has never 
been a greater need to undertake a high quality systematic review (with meta-analysis 
where appropriate) that can guide future research and practice for preventing and 
managing RD. Future research efforts/investment should be directed to the few most 
promising interventions that may have been reported as effective by at least one trial.  
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